The potential of such molecules for the treatment of asthma or chronic obstructive pulmonary disease was evidenced with the use of LC-HN/C linked to epidermal growth factor (LC-HN/C-EGF) inhibiting the release of mucin by pulmonary epithelial A549 cells (COPD) [93]. This evidence concerns the gene EGF and asthma.